Merz Dermatology has launched a co-payment savings program designed to enhance the affordability of naftifine HCl (Naftin) topical antifungal treatments.
The program is designed to benefit dermatology patients with high-deductible insurance plans. At the beginning of a new calendar year, patients with high-deductible plans are required by their insurer to pay significant out-of-pocket costs until their deductible is met. With this program, the majority of eligible insured patients can expect a co-pay of no more than $15 for a naftifine HCl prescription.
Naftifine HCl) Gel 2%, which improves on the original formulation of Naftin® (naftifine HCl) Gel 1% by delivering the efficacy of naftifine hydochloride with a once-daily application treatment regimen, is most recent addition to the line.
“Merz is dedicated to advancing the quality of care in the medical dermatology space, and we are especially committed to facilitating patient access to effective, high-quality treatment options, regardless of the patient’s financial situation,” explains Greg Besase, Vice President and Head of US Dermatology for Merz North America. “Our co-payment savings program is simply one more way for us to demonstrate our commitment to the patients and physicians who benefit from our medical dermatology products.”
For more information, please visit www.Naftin.com.
